Hyperglycemia Exacerbates Periodontal Destruction via Systemic Suppression of Regulatory T Cell Number and Function DOI
Masami Saotome, Ryutaro Kuraji, Yukihiro Numabe

et al.

Journal of Periodontal Research, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

ABSTRACT Aim Diabetes is a significant risk factor that exacerbates the pathological progression of periodontal disease. In recent years, attention has focused on effect regulatory T cells (Tregs), which play central role in immune tolerance, inflammatory processes tissue, suggesting link with diabetes‐associated periodontitis. this study, we examined dynamics Tregs tissue mice streptozotocin (STZ)‐induced hyperglycemia. Methods Eleven‐week‐old male C57BL/6J were divided into four treatment groups: Untreated (C group), ligature placed around maxillary second molars silk sutures (PD intraperitoneal administration STZ (HG and after (PHG group). Establishment hyperglycemia was assessed 14 days administration, ligation performed 7 later. After another ligation, euthanized. The right side maxilla observed histopathologically, whereas palatal gingiva left analyzed genetically, microstructure alveolar bone also assessed. addition, lymphocytes from peripheral blood, spleen, using flow cytometry. Results structure analyses, height, volume/tissue volume (BV/TV), mineral density (BMD) lower PHG group than PD group. gingival expression Foxp3 gene up‐regulated compared C group, IL‐17a Flow cytometry analyses showed number (CD4 + CD25 cells) blood significantly higher groups CD4 − cells, are reportedly functionally attenuated as Tregs, increased Immunofluorescence staining only trend toward an Conclusion present study STZ‐induced numerically attenuates mouse model experimental Furthermore, impaired tolerance capacity appears to be involved exacerbating inflammation destruction tissue.

Language: Английский

Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders DOI
Azhagu Madhavan Sivalingam

Clinical Reviews in Allergy & Immunology, Journal Year: 2025, Volume and Issue: 68(1)

Published: Feb. 11, 2025

Language: Английский

Citations

0
A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief review DOI Creative Commons

María Fernanda Segovia,

Diana Landoni,

Yohana Defranchi

et al.

Exploration of Immunology, Journal Year: 2025, Volume and Issue: 5

Published: March 4, 2025

In hematological malignancies, autologous immunotherapy with T lymphocytes expressing a chimeric antigen receptor (CAR-T) has been successfully applied. CAR enhances the immuno-cellular effector system directly against cells target antigens. The objective here was to discuss prospects of applying CAR-T and its variants in autoimmune diseases (AIDs) deplete pathogenic autoantibodies by eliminating B plasma cells. play crucial role pathogenesis AID through production autoantibodies, cytokine dysregulation, presentation, regulatory dysfunction. numerous autoreactive clones various autoantigens, such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, myositis, sclerosis, targeting CD19/CD20 B-cell maturation (BCMA) have shown success preclinical clinical studies, representing an innovative option for refractory patients when standard treatments fail. suppression reactive specific antigens using cytolytic carrying autoantibody (CAAR-T) offers promising approach managing AIDs, especially those characterized pemphigus vulgaris, myasthenia gravis, anti-NMDAR encephalitis. CAAR-T allows elimination without compromising general functionality immune system, minimizing common side effects immunosuppressive therapies, including immunobiologicals CAR-T. vitro, preclinical, (phase 1) studies demonstrated efficacy specificity several AIDs; however, extensive trials 3) are required assess their safety applicability. These advances promise enhance precision medicine management offering personalized individual patients.

Language: Английский

Citations

0
Regulatory T cell-based therapies for type 1 diabetes: a narrative review DOI Open Access
Tsvetelina Velikova, Georgi Vasilev,

Diya Linkwinstar

et al.

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(2)

Published: April 1, 2025

Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of pancreatic insulin-secreting beta cells, resulting in hyperglycemia and a lifelong need for exogenous insulin therapy. Regulatory T cells (Tregs) are essential maintaining immune tolerance preventing reactions. It has been shown that dysfunctional Tregs participate pathophysiology T1D. Therapeutic approaches designed to enhance Treg stability, survival, function have progressively emerged as promising treatment strategy This narrative review explores potential cell-based therapy therapeutic tool alter natural history discusses different pharmacological strategies stability function, well latest advances therapies, including adoptive cell genetic engineering Tregs. also outlines current challenges future research directions integrating into clinical practice, aiming provide comprehensive overview its benefits limitations innovative intervention

Language: Английский

Citations

0
Exploiting regulatory T cells (Tregs): Cutting-edge therapy for autoimmune diseases DOI Creative Commons
Marwa Hassan, Mohamed Elzallat, Dina Mostafa Mohammed

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 155, P. 114624 - 114624

Published: April 10, 2025

Regulatory T cells (Tregs) are a specialized subset of suppressive that essential for maintaining self-tolerance, regulating effector cells, managing microbial infections, preventing tumors, allergies, and autoimmune disorders, facilitating allograft transplantation. Disruptions in Treg function or abundance contribute to an imbalance between pathogenic protective immune diseases. Recently, one promising treatment strategy restore balance involves the selective expansion manipulation Tregs using low-dose IL-2 therapy, adoptive cell transfer, chimeric antigen receptor (CAR)-Treg approaches. have been shown increasing number research studies prevent even treat variety such as allergic diseases, transplant rejection, graft-versus-host disease. A thorough comprehension is anticipated provide clear prospects effective immunotherapy wide range This review provides overview biology, including their functions, mechanisms, phenotypic markers, well involvement disease settings. Furthermore, we discuss therapeutic potential different subpopulations translational applications

Language: Английский

Citations

0
Chimeric antigen receptor T-cell therapy in autoimmune diseases DOI Creative Commons
Jie Liu, Zhao Yan, Zhao Hai

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 19, 2024

The administration of T cells that have been modified to carry chimeric antigen receptors (CARs) aimed at B has an effective strategy in treating cell malignancies. This breakthrough spurred the creation CAR intended specifically reduce or alter faulty immune responses associated with autoimmune disorders. Early positive outcomes from clinical trials involving target protein CD19 patients suffering diseases driven by reported. Additional strategies are being developed broaden use therapy and enhance its safety conditions. These include employing autoantireceptors (CAAR) eliminate reactive autoantigens, using regulatory (Tregs) engineered antigen-specific CARs for precise modulation. discussion emphasizes key factors such as choosing right groups, designing constructs, defining tolerable side effects, achieving a lasting modification, all which critical safely integrating diseases.

Language: Английский

Citations

1
Hyperglycemia Exacerbates Periodontal Destruction via Systemic Suppression of Regulatory T Cell Number and Function DOI
Masami Saotome, Ryutaro Kuraji, Yukihiro Numabe

et al.

Journal of Periodontal Research, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

ABSTRACT Aim Diabetes is a significant risk factor that exacerbates the pathological progression of periodontal disease. In recent years, attention has focused on effect regulatory T cells (Tregs), which play central role in immune tolerance, inflammatory processes tissue, suggesting link with diabetes‐associated periodontitis. this study, we examined dynamics Tregs tissue mice streptozotocin (STZ)‐induced hyperglycemia. Methods Eleven‐week‐old male C57BL/6J were divided into four treatment groups: Untreated (C group), ligature placed around maxillary second molars silk sutures (PD intraperitoneal administration STZ (HG and after (PHG group). Establishment hyperglycemia was assessed 14 days administration, ligation performed 7 later. After another ligation, euthanized. The right side maxilla observed histopathologically, whereas palatal gingiva left analyzed genetically, microstructure alveolar bone also assessed. addition, lymphocytes from peripheral blood, spleen, using flow cytometry. Results structure analyses, height, volume/tissue volume (BV/TV), mineral density (BMD) lower PHG group than PD group. gingival expression Foxp3 gene up‐regulated compared C group, IL‐17a Flow cytometry analyses showed number (CD4 + CD25 cells) blood significantly higher groups CD4 − cells, are reportedly functionally attenuated as Tregs, increased Immunofluorescence staining only trend toward an Conclusion present study STZ‐induced numerically attenuates mouse model experimental Furthermore, impaired tolerance capacity appears to be involved exacerbating inflammation destruction tissue.

Language: Английский

Citations

0